US20020110600A1 - Composition for treating symptoms of influenza - Google Patents
Composition for treating symptoms of influenza Download PDFInfo
- Publication number
- US20020110600A1 US20020110600A1 US09/783,027 US78302701A US2002110600A1 US 20020110600 A1 US20020110600 A1 US 20020110600A1 US 78302701 A US78302701 A US 78302701A US 2002110600 A1 US2002110600 A1 US 2002110600A1
- Authority
- US
- United States
- Prior art keywords
- composition
- homeopathic
- leaf extract
- blend
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
Definitions
- the invention relates to the field of natural compositions, particularly herbal compositions, for treating symptoms of influenza.
- Oleuropein is a bitter glucoside found in olives and the roots, leaves and bark of the olive tree, Olea europaea .
- Medicinal use of this extract dates back to the early 1800s when it was used in liquid form as a treatment for malarial infections.
- Oleuropein undergoes mild acid hydrolysis to form elenolic acid, this process being similar to an enzyme based hydrolysis of the compound which takes place in the human body.
- a salt of elenolic acid, calcium elenolate was reported to have in vitro antiviral activity in an article by Renis, “In Vitro Antiviral Activity of Calcium Elenolate,” Antimicrobial Agents and Chemotherapy 10 1969, pages 167-172. In this article, calcium elenolate was reported to have activity against a wide variety of viruses, with the greatest activity under alkaline conditions (pH 7.5).
- U.S. Pat. No. 5,714,150 discloses a method for extracting oleuropein from olive leaves in a form which retains medicinal activity in vivo, with multiple extractions taking place with a hydroethanolic solvent, followed by distillation under vacuum to produce and concentrate, and then drying. The steps take place at about 20 to 88° C.
- the invention is directed to a composition for relief of symptoms of colds and influenza, comprising, by weight, about 80-88% olive leaf extract powder containing oleuropein, about 5-10% neem leaf powder and about 4-8% of a homeopathic blend for symptom relief, and which preferably comprises one or more components from the group aconitum napelius, belladonna, eupatorium perfoliatum, gelsemium sermpervirens, Echinacea angustifolia and ferrum phosphoricum.
- the invention also relates to a method of substantially eliminating or ameliorating the symptoms of viral and microbial illness of human patients comprising administering to a human patient in need of thereof an effective amount of a composition such as set forth above.
- the major ingredient of the composition of the invention is an olive leaf extract powder, the olive leaf preferably extracted according to the disclosure of U.S. Pat. No. 5,714,150, which is incorporated herein by reference.
- olive leaves are treated with an alcohol and water solution to produce an alcoholic extract, the alcohol and water solution is drained from the olive leaves, the olive leaves are treated with fresh alcohol and water solution at least two more times, the hydroethanolic extracts produced are then combined and distilled under vacuum at a temperature of about 20° to 88° C. to produce a concentrated extract having a solids content of about 30 to 40%.
- the concentrated extract can then be spray dried or oven dried under vacuum to produce a dry powder extract comprising approximately 30-40% by weight oleuropein.
- these process steps must be conducted at a temperature no greater than about 88° C., since destruction of the effective glucoside is thought to occur at higher temperatures. It is thought that by conducting a plurality of low temperature hydroethanolic extractions followed by a low temperature distillation, the resultant oleuropein contains a high proportion of R-oleuropein as compared with L-oleuropein, the d-oleuropein not binding to amino acids or serum proteins in the human body, and therefore remaining active in vivo.
- the olive leaf concentrate can also be dried by freeze drying. Applicants believe that a more potent extract can be obtained by freeze drying.
- the composition of the invention will contain about 80-88% by weight olive leaf extract powder, preferably about 84-86% by weight.
- composition of the invention will also contain about 5-10% by weight neem leaf extract.
- the neem tree also known as Azadiracha indica , has for many centuries been a source of herbal medicines on the Indian subcontinent.
- a number of uses for neem extracts are known, including the use of neem oil as an insect repellant (U.S. Pat. No. 5,885,600) and the use of neem extract for healing the skin (U.S. Pat. No. 6,126,950).
- composition of the invention contains about 5-10% by weight of a hydroethanolic extract of neem leaf, dried to a powder form.
- This material is available commercially from, for example, Rym Exports of Worli, Mumbai, India.
- the composition of the invention also contains up to about 8% by weight of a homeopathic blend useful in reducing symptoms of colds and fevers.
- a preferred blend contains aconitum napelius , belladonna, eupatorium perfoliatum, gelsemium sempervirens, Echinacea angostifolia and ferrum phosphoricum.
- Aconitum napelius, belladonna and ferrum phosphoricum are used for treatment of fever
- eupatorium perfoliatum and gelsemium sempervirens are used to relieve symptoms of aches and pains, headaches and trembling
- Echinacea angustifolia is used for treatment of infections.
- This blend is typically added in an amount of about 6-8% by weight.
- Other blends including some of the above materials, or other material for the same general purposes may also be used in effective amounts.
- compositions of the invention will typically contain pharmaceutically acceptable excipients of the type well known in the art necessary for proper tableting of the composition. Such excipients may make up about 10-20% by weight of the final tablet.
- a typical tablet or capsule according to the invention will contain about 500 mg olive leaf extract powder, 50 mg neem leaf extract powder and 40 mg of the homeopathic blend, all weights ⁇ 10%.
- the adult dosage of this composition is 2 tablets or capsules, 4 times a day, at the first sign of a cold or flu, taken with a large quantity of water. While symptoms may disappear rapidly, the treatment should be continued for at least three days for best effect.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
- The invention relates to the field of natural compositions, particularly herbal compositions, for treating symptoms of influenza.
- Colds and influenza are major causes of illness and loss of productivity both within the United States, and throughout the world at large. Approximately 10-15% of adult colds are thought to be caused by viruses which are also responsible for other serious illnesses, including influenza.
- An effective treatment for a wide variety of illnesses caused by viruses and bacteria has long been sought, both in terms of antiviral and antimicrobial action, and in terms of symptom relief. Some traditional Chinese medicine herbal formulas have been found somewhat effective in this regard, as is disclosed, for example, in U.S. Pat. Nos. 5,834,000, 5,989,556 and 6,083,291. Some of the traditional compositions have contained stimulants such as caffeine and ephedrine, which have proved to be undesirable.
- One material which has been found to have antiviral properties is oleuropein. Oleuropein is a bitter glucoside found in olives and the roots, leaves and bark of the olive tree,Olea europaea. Medicinal use of this extract dates back to the early 1800s when it was used in liquid form as a treatment for malarial infections. Oleuropein undergoes mild acid hydrolysis to form elenolic acid, this process being similar to an enzyme based hydrolysis of the compound which takes place in the human body. A salt of elenolic acid, calcium elenolate, was reported to have in vitro antiviral activity in an article by Renis, “In Vitro Antiviral Activity of Calcium Elenolate,” Antimicrobial Agents and Chemotherapy 10 1969, pages 167-172. In this article, calcium elenolate was reported to have activity against a wide variety of viruses, with the greatest activity under alkaline conditions (pH 7.5).
- However, when incubation was carried out with amino acids prior to incubation with virus, losses in virucidal activity were detected, especially in the presence of glycine, lysine, cysteine and histidine, and to a lesser extent with other amino acids. More recently, oleuropein has been found to be effective, in-vitro, againstSalmonella enteritidis (“Inhibition of Salmonella enteritidis by oleuropein in broth and in a model foodsystem,” Lett Appl Microbiol 20(2):120-4, February 1995), and enterotoxin B (“The effect of the olive phenolic compound, oleuropein, on growth and enterotoxin B production,” J. Appl. Bacteriology 74(3):253-9, March 1993). In addition, oleuropein has been found to protect low density lipoprotein from oxidation (Life Sci 55(24):1965-71, 1994) and to inhibit platelet aggregation (Thromb Res 78(2):151-60, Apr. 15, 1995). U.S. Pat. No. 5,714,150 discloses a method for extracting oleuropein from olive leaves in a form which retains medicinal activity in vivo, with multiple extractions taking place with a hydroethanolic solvent, followed by distillation under vacuum to produce and concentrate, and then drying. The steps take place at about 20 to 88° C.
- It is therefore an object of the invention to provide a pharmacologically effective composition which is effective against a broad spectrum of viruses and bacteria.
- It is another object of the invention to provide a composition which is completely plant based in nature and does not contain caffeine, ephedrine, or similar undesirable components.
- It is a further object of the invention to provide a composition which alleviates symptoms of colds and influenza.
- To achieve these and other objects, the invention is directed to a composition for relief of symptoms of colds and influenza, comprising, by weight, about 80-88% olive leaf extract powder containing oleuropein, about 5-10% neem leaf powder and about 4-8% of a homeopathic blend for symptom relief, and which preferably comprises one or more components from the groupaconitum napelius, belladonna, eupatorium perfoliatum, gelsemium sermpervirens, Echinacea angustifolia and ferrum phosphoricum.
- The invention also relates to a method of substantially eliminating or ameliorating the symptoms of viral and microbial illness of human patients comprising administering to a human patient in need of thereof an effective amount of a composition such as set forth above.
- The major ingredient of the composition of the invention is an olive leaf extract powder, the olive leaf preferably extracted according to the disclosure of U.S. Pat. No. 5,714,150, which is incorporated herein by reference. In that process, olive leaves are treated with an alcohol and water solution to produce an alcoholic extract, the alcohol and water solution is drained from the olive leaves, the olive leaves are treated with fresh alcohol and water solution at least two more times, the hydroethanolic extracts produced are then combined and distilled under vacuum at a temperature of about 20° to 88° C. to produce a concentrated extract having a solids content of about 30 to 40%. The concentrated extract can then be spray dried or oven dried under vacuum to produce a dry powder extract comprising approximately 30-40% by weight oleuropein.
- Importantly, these process steps must be conducted at a temperature no greater than about 88° C., since destruction of the effective glucoside is thought to occur at higher temperatures. It is thought that by conducting a plurality of low temperature hydroethanolic extractions followed by a low temperature distillation, the resultant oleuropein contains a high proportion of R-oleuropein as compared with L-oleuropein, the d-oleuropein not binding to amino acids or serum proteins in the human body, and therefore remaining active in vivo.
- In keeping with the low temperature processing requirements, the olive leaf concentrate can also be dried by freeze drying. Applicants believe that a more potent extract can be obtained by freeze drying. The composition of the invention will contain about 80-88% by weight olive leaf extract powder, preferably about 84-86% by weight.
- The composition of the invention will also contain about 5-10% by weight neem leaf extract. The neem tree, also known asAzadiracha indica, has for many centuries been a source of herbal medicines on the Indian subcontinent. A number of uses for neem extracts are known, including the use of neem oil as an insect repellant (U.S. Pat. No. 5,885,600) and the use of neem extract for healing the skin (U.S. Pat. No. 6,126,950).
- The composition of the invention contains about 5-10% by weight of a hydroethanolic extract of neem leaf, dried to a powder form. This material is available commercially from, for example, Rym Exports of Worli, Mumbai, India.
- Preferably, the composition of the invention also contains up to about 8% by weight of a homeopathic blend useful in reducing symptoms of colds and fevers. A preferred blend containsaconitum napelius, belladonna, eupatorium perfoliatum, gelsemium sempervirens, Echinacea angostifolia and ferrum phosphoricum. Aconitum napelius, belladonna and ferrum phosphoricum are used for treatment of fever, eupatorium perfoliatum and gelsemium sempervirens are used to relieve symptoms of aches and pains, headaches and trembling, and Echinacea angustifolia is used for treatment of infections. This blend is typically added in an amount of about 6-8% by weight. Other blends including some of the above materials, or other material for the same general purposes may also be used in effective amounts.
- In addition to the above ingredients, the compositions of the invention will typically contain pharmaceutically acceptable excipients of the type well known in the art necessary for proper tableting of the composition. Such excipients may make up about 10-20% by weight of the final tablet.
- A typical tablet or capsule according to the invention will contain about 500 mg olive leaf extract powder, 50 mg neem leaf extract powder and 40 mg of the homeopathic blend, all weights ±10%. The adult dosage of this composition is 2 tablets or capsules, 4 times a day, at the first sign of a cold or flu, taken with a large quantity of water. While symptoms may disappear rapidly, the treatment should be continued for at least three days for best effect.
- While not wishing to be held to any particular theory, Applicants recognize that various olive extracts have been known to be effective against viruses for many years, and the neem leaf which has been long used in Asia for symptom relief, is thought to provide additional bacteriacidal and virucidal properties.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/783,027 US6455070B1 (en) | 2001-02-15 | 2001-02-15 | Composition for treating symptoms of influenza |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/783,027 US6455070B1 (en) | 2001-02-15 | 2001-02-15 | Composition for treating symptoms of influenza |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020110600A1 true US20020110600A1 (en) | 2002-08-15 |
US6455070B1 US6455070B1 (en) | 2002-09-24 |
Family
ID=25127955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/783,027 Expired - Fee Related US6455070B1 (en) | 2001-02-15 | 2001-02-15 | Composition for treating symptoms of influenza |
Country Status (1)
Country | Link |
---|---|
US (1) | US6455070B1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040191337A1 (en) * | 2003-03-26 | 2004-09-30 | Council Of Scientific And Industrial Research | Nontoxic dental care herbal formulation for preventing dental plaque and gingivitis |
WO2010130869A1 (en) * | 2009-05-14 | 2010-11-18 | Sanidad Y Residencias 21, S. A. | Use of olive leaf extracts in a pharmaceutical composition for inducing angiogenesis and vasculogenesis |
WO2011141611A1 (en) | 2010-05-14 | 2011-11-17 | Sanidad Y Residencias 21, S.A., | Oleuropein compositions for healing wounds and ulcers in elderly people and/or diabetics |
CN105461730A (en) * | 2014-09-09 | 2016-04-06 | 中国人民解放军第二军医大学 | Gelsepyrrodine compounds, and preparation method and application thereof |
CN107913300A (en) * | 2018-01-19 | 2018-04-17 | 河南牧农生物科技有限公司 | A kind of formula for treating poultry influenza ewcastle disease |
US11331265B2 (en) * | 2015-12-01 | 2022-05-17 | Shodoshima Healthyland Co., Ltd. | Ultraviolet blocking agent and cosmetic product |
WO2022149619A1 (en) * | 2020-12-11 | 2022-07-14 | Bigham Herman Lee Jr | Covid 19 virus/flu aerosol spray composition and methods for combating, contracting and spreading of viruses and colds |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9072753B1 (en) * | 2000-04-03 | 2015-07-07 | Amy C. Brown | Gargle method to reduce the duration of common cold symptoms |
FR2853549B1 (en) * | 2003-04-11 | 2007-11-09 | Agronomique Inst Nat Rech | NUTRITIONAL OR THERAPEUTIC COMPOSITION CONTAINING THE OLEUROPE COMPOUND OR ONE OF ITS DERIVATIVES |
US20050191371A1 (en) * | 2004-02-12 | 2005-09-01 | Rizo Andres M. | Medical composition |
KR20070097274A (en) * | 2006-03-28 | 2007-10-04 | 메드. 클라우스 휴버 닥터. | Drug and/or food supplement containing nisylen, cepa, euphrasia, belladonna and/or mercurius solubilis |
DE202006004962U1 (en) * | 2006-03-28 | 2007-08-02 | Huber, Klaus, Dr.med. | Use of Nisylene, Cepa, Euphrasia, Belladonna and / or Mercurius solubilis for a medicinal product |
KR100834444B1 (en) | 2007-01-15 | 2008-06-09 | 원광대학교산학협력단 | Pharmaceutical composition comprising oleuropein isolated from fraxinus rhynchophylla for prevention and treating toxoplasmosis |
FR2937538B1 (en) * | 2008-10-23 | 2010-12-31 | Muselier Corinne Treger | ANTIGRIPPAL PRODUCT |
CA3201770A1 (en) * | 2020-12-08 | 2022-06-16 | Roberto Crea | Antiviral olive extract compositions and methods |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837257A (en) | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
US5714150A (en) | 1997-01-08 | 1998-02-03 | Nachman; Leslie | Method for producing extract of olive leaves |
US5885600A (en) | 1997-04-01 | 1999-03-23 | Burlington Bio-Medical & Scientific Corp. | Natural insect repellent formula and method of making same |
US5834000A (en) | 1997-04-11 | 1998-11-10 | Yng-Wong; Quing Non | Antiviral and antimicrobial herbal complex |
IN1997DE01715A (en) | 1997-06-24 | 2015-07-31 | Council Scient Ind Res | |
US6083921A (en) | 1998-01-12 | 2000-07-04 | Xu; Kai Jian | Pharmaceutical compositions and method of using same |
IT1298283B1 (en) | 1998-02-19 | 1999-12-20 | B & T S R L | USE OF THE EXTRACT OF EUROPEAN OIL LEAVES AS ANTI-RADICAL |
-
2001
- 2001-02-15 US US09/783,027 patent/US6455070B1/en not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040191337A1 (en) * | 2003-03-26 | 2004-09-30 | Council Of Scientific And Industrial Research | Nontoxic dental care herbal formulation for preventing dental plaque and gingivitis |
US7083779B2 (en) | 2003-03-26 | 2006-08-01 | Council Of Scientific And Industrial Research | Nontoxic dental care herbal formulation for preventing dental plaque and gingivitis |
WO2010130869A1 (en) * | 2009-05-14 | 2010-11-18 | Sanidad Y Residencias 21, S. A. | Use of olive leaf extracts in a pharmaceutical composition for inducing angiogenesis and vasculogenesis |
ES2349976A1 (en) * | 2009-05-14 | 2011-01-13 | Sanidad Y Residencias 21 Sa | Use of olive leaf extracts in a pharmaceutical composition for inducing angiogenesis and vasculogenesis |
WO2011141611A1 (en) | 2010-05-14 | 2011-11-17 | Sanidad Y Residencias 21, S.A., | Oleuropein compositions for healing wounds and ulcers in elderly people and/or diabetics |
CN105461730A (en) * | 2014-09-09 | 2016-04-06 | 中国人民解放军第二军医大学 | Gelsepyrrodine compounds, and preparation method and application thereof |
US11331265B2 (en) * | 2015-12-01 | 2022-05-17 | Shodoshima Healthyland Co., Ltd. | Ultraviolet blocking agent and cosmetic product |
CN107913300A (en) * | 2018-01-19 | 2018-04-17 | 河南牧农生物科技有限公司 | A kind of formula for treating poultry influenza ewcastle disease |
WO2022149619A1 (en) * | 2020-12-11 | 2022-07-14 | Bigham Herman Lee Jr | Covid 19 virus/flu aerosol spray composition and methods for combating, contracting and spreading of viruses and colds |
Also Published As
Publication number | Publication date |
---|---|
US6455070B1 (en) | 2002-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5714150A (en) | Method for producing extract of olive leaves | |
Khare | Indian herbal remedies: rational Western therapy, ayurvedic, and other traditional usage, Botany | |
Sabandar et al. | Medicinal property, phytochemistry and pharmacology of several Jatropha species (Euphorbiaceae): a review | |
US6455070B1 (en) | Composition for treating symptoms of influenza | |
JP2001516337A (en) | Antivirals from plant extracts and uses for the treatment of viral infections | |
US20190008906A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
CN113244296B (en) | Medicinal volatile oil composition and preparation method and application thereof | |
KR20080105825A (en) | Herb composition useful for arthritis treatment or prevention and preparation thereof | |
WO2006118553A1 (en) | Compositions comprising natural agents for the treatment of hiv-associated opportunistic infections and complications and methods for preparing and using compositions comprising natural agents | |
Fisher | Materia medica of Western herbs | |
Islam et al. | A review on medicinal uses of different plants of Euphorbiaceae family | |
US20060233895A1 (en) | Herbal remedy for treating Lyme disease | |
US6440451B1 (en) | Use of crataegus formulations for prophylaxis and treatment of neoplastic diseases | |
Yarnell | Stinging nettle: a modern view of an ancient healing plant | |
KR20160043430A (en) | Composition for preventing hair loss, promoting hair generation, or enhancing moist and glossy of hair and manufacturing method thereof | |
RU2303992C1 (en) | Curative-prophylactic remedy for youngsters of farm animals and method for preventing and treating respiratory diseases in calves due to its application | |
CN107362271A (en) | A kind of Chinese medicine composition for treating breathing problem and preparation method thereof | |
RU2303993C1 (en) | Treatment and prophylaxis means applicable for treating young agricultural animals and method for preventing and treating calves for gastrointestinal tract diseases | |
JPH08151329A (en) | Antiviral agent, carcinostatic agent and production thereof | |
CN106728069B (en) | Slough-removing and tissue regeneration-promoting paste for treating scalds and burns | |
RU2311190C1 (en) | Therapeutical and prophylactic drug for young agricultural animals and a method to prevent and treatment of viral respiratory diseases in calves using it | |
KR20190119020A (en) | A composition for anti-inflammation comprising hemistepta lyrata extract | |
CN103446564A (en) | Traditional Chinese medicine composition for antisepsis and antiinflammation and preparation method thereof | |
Miroshina et al. | Echinacea purpurea as a medicinal plant: characteristics, use as a biologically active component of feed additives and specialized foods | |
Elisée et al. | Qualitative Phytochemical Study and Evaluation of The Healing Activity of The Combined Crude Aqueous Extracts of Two Asteraceae: Chromolaena Odorata and Thitonia Diversifolia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: EAST PARK RESEARCH, INC., NEVADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VOORHEES, JOHN;REEL/FRAME:011597/0539 Effective date: 20010301 |
|
AS | Assignment |
Owner name: EAST PARK RESEARCH, INC., NEVADA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NAMES OF THE ASSIGNORS. FILED ON MARCH 12, 2001, RECORDED ON REEL 11597 FRAME 0539;ASSIGNORS:VOORHEES, JOHN;NACHMAN, LESLIE;REEL/FRAME:011867/0506 Effective date: 20010301 |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20140924 |